Publications

The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
Neurosurgery 2015 Aug;77(2):248-53; discussion 253
Departments of *Neurological Surgery, ‡Epidemiology and Biostatistics, and §Neurology, University of California at San Francisco, San Francisco, California.

Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence.
Neurosurgery 2015 Aug;62 Suppl 1:160-5
*Department of Neurological Surgery, ‡Department of Epidemiology and Biostatistics, and §Department of Neurology, University of California, San Francisco, San Francisco, California.

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Neuro Oncol 2014 Sep 26;16(9):1255-62. Epub 2014 Mar 26.
Department of Neurological Surgery, University of California, San Francisco, California (S.J.H., J.D.R., A.M.M., J.L.C., M.D.P., S.M.C., M.S.B., A.D., N.A.B.); Department of Epidemiology and Biostatistics, University of California, San Francisco, California (A.M.M.).


Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
J Neurooncol 2016 12 13;130(3):543-552. Epub 2016 Sep 13.
Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Ave, M-779, San Francisco, CA, 94143, USA.

OF